Iovance Biotherapeutics, Inc.
IOVA
$3.89
-$0.15-3.71%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 8.47% | -9.23% | -14.99% | -2.82% | 32.50% |
| Total Depreciation and Amortization | -26.33% | 15.20% | 9.89% | 11.69% | 76.69% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -55.67% | -64.82% | -12.96% | 42.69% | 191.99% |
| Change in Net Operating Assets | 83.22% | 30.65% | 123.74% | 45.84% | -465.55% |
| Cash from Operations | 28.28% | -33.45% | 31.48% | 15.20% | 12.71% |
| Capital Expenditure | -123.61% | -373.95% | -1,588.01% | -48.91% | -18.11% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -100.00% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -63.75% | 159.89% | -47.61% | 140.32% | 140.03% |
| Cash from Investing | -96.73% | 134.86% | -65.58% | 114.23% | 132.50% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1,675.38% | 83.54% | -91.07% | -24.87% | 177.79% |
| Repurchase of Common Stock | 49.43% | 92.58% | 49.60% | -20.06% | -373.12% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 2,332.74% | 109.89% | -91.34% | -25.96% | 140.02% |
| Foreign Exchange rate Adjustments | 148.98% | -154.27% | 691.20% | 203.46% | -138.99% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 110.23% | 139.78% | -141.95% | 237.58% | 68.27% |